► Additional material is

published online only. To view

please visit the journal online

(http://dx.doi.org/10.1136/

<sup>1</sup>Department of Cardiology,

Bern University Hospital, Bern,

<sup>2</sup>Department of Cardiovascular

Surgery, Swiss Cardiovascular

Center Bern, Bern University

Hospital, Bern, Switzerland

<sup>3</sup>Institute of Social and

Preventive Medicine and Clinical Trials Unit, Bern

University Hospital, Bern,

Correspondence to

Department of Cardiology,

Swiss Cardiovascular Center

CH-3010 Bern, Switzerland;

peter.wenaweser@insel.ch

Received 28 April 2014

Revised 4 August 2014

Published Online First 27 August 2014

Accepted 5 August 2014

Bern, Bern University Hospital,

Dr Peter Wenaweser,

heartinl-2014-306106).

Switzerland

Switzerland

## ORIGINAL ARTICLE

## Long-term outcome of elderly patients with severe aortic stenosis as a function of treatment modality

Thomas Pilgrim,<sup>1</sup> Lars Englberger,<sup>2</sup> Martina Rothenbühler,<sup>3</sup> Stefan Stortecky,<sup>1</sup> Osman Ceylan,<sup>1</sup> Crochan J O'Sullivan,<sup>1</sup> Christoph Huber,<sup>2</sup> Fabien Praz,<sup>1</sup> Lutz Buellesfeld,<sup>1</sup> Bettina Langhammer,<sup>2</sup> Bernhard Meier,<sup>1</sup> Peter Jüni,<sup>3</sup> Thierry Carrel,<sup>2</sup> Stephan Windecker,<sup>1</sup> Peter Wenaweser<sup>1</sup>

#### ABSTRACT

**Objective** To assess long-term clinical outcomes of consecutive high-risk patients with severe aortic stenosis according to treatment allocation to transcatheter aortic valve implantation (TAVI), surgical aortic valve replacement (SAVR) or medical treatment (MT).

**Methods** Patients with severe aortic stenosis were consecutively enrolled into a prospective single centre registry.

Results Among 442 patients (median age 83 years. median STS-score 4.7) allocated to MT (n=78), SAVR (n=107), or TAVI (n=257) all-cause mortality amounted to 81%, 37% and 43% after a median duration of follow-up of 3.9 years (p<0.001). Rates of major adverse cerebro-cardiovascular events were lower in patients undergoing SAVR or TAVI as compared with MT (SAVR vs MT: HR 0.31, 95% CI 0.21 to 0.46) (TAVI vs MT: HR 0.34, 95% CI 0.25 to 0.46), with no significant difference between SAVR and TAVI (HR 0.88, 95% CI 0.62 to 1.25). Whereas SAVR (HR 0.39, 95% CI 0.24 to 0.61), TAVI (HR 0.37, 95% CI 0.26 to 0.52), and female gender (HR 0.72, 95% CI 0.53 to 0.99) were associated with improved survival, body mass index  $\leq 20 \text{ kg/m}^2$  (HR 1.60, 95% CI 1.04 to 2.47), diabetes (HR 1.48, 95% CI 1.03 to 2.12), peripheral vascular disease (HR 2.01, 95% CI 1.44 to 2.81), atrial fibrillation (HR 1.74, 95% CI 1.28 to 2.37) and pulmonary hypertension (HR 1.43, 95% CI 1.03 to 2.00) were identified as independent predictors of mortality.

**Conclusions** Among high-risk patients with severe aortic stenosis, long-term clinical outcome through 5 years was comparable between patients allocated to SAVR or TAVI. In contrast, patients with MT had a dismal prognosis.

#### INTRODUCTION

Transcatheter aortic valve implantation (TAVI) has evolved into a valuable treatment option among elderly patients with symptomatic valvular aortic stenosis at high surgical risk. Evidence from randomised clinical trials showed a sustained survival benefit of TAVI compared with medical treatment (MT) in inoperable patients as well as similar survival as surgical aortic valve replacement (SAVR) among patients at high risk for surgery through 2 years of follow-up.<sup>1</sup><sup>2</sup> However, data on longterm clinical outcomes of patients undergoing TAVI remain sparse and the rate of adverse events is largely determined by comorbidities. Long-term efficacy data of TAVI compared with surgical treatment are important to further refine the clinical selection process of TAVI candidates and to supplement in vitro data on valve durability.

We have previously reported the outcome of unselected patients allocated to a particular treatment strategy (MT, SAVR or TAVI) and presented periprocedural and midterm clinical outcome.<sup>3</sup> The aim of the present analysis was to extend these observations during long-term follow-up through 5 years according to initial treatment allocation and to identify predictors of adverse clinical outcomes.

#### METHODS

#### Patient population

Between July 2007 and September 2010, all patients with symptomatic, severe aortic stenosis deemed at increased surgical risk were consecutively enrolled into a prospective single centre registry. Criteria for inclusion have been reported previously<sup>3</sup> and are summarised in the online supplementary material. All subjects provided written informed consent and the study was approved by the local ethical committee.

#### Interdisciplinary evaluation and selection of a treatment strategy

Patients with severe aortic stenosis at increased surgical risk underwent a multimodal assessment according to a standardised protocol during a short hospitalisation (see online supplementary material). Selection of an appropriate treatment strategy was based on a consensus decision within the Heart Team.

MT consisted of treatment of cardiac and noncardiac comorbidities according to best clinical practice. In patients with severe coronary artery disease and limiting angina, percutaneous coronary intervention was performed as indicated. Balloon aortic valvuloplasty was not offered as part of the MT strategy, nor as a bridge to SAVR in patients with congestive heart failure. In some cases, treatment allocation was reconsidered and discussed in the Heart Team. As a consequence some patients underwent TAVI or SAVR at a later stage.

SAVR was performed according to contemporary standards as outlined previously.<sup>3</sup>

TAVI was performed with either the Medtronic CoreValve Revalving system or the Edwards SAPIEN valve through a transfemoral, transapical

CrossMark

**To cite:** Pilgrim T, Englberger L, Rothenbühler M, *et al. Heart* 2015;**101**:30–36.



or a trans-subclavian access using standard techniques. The algorithm for access and device selection according to annulus diameter and vascular access dimensions has been reported previously.<sup>3</sup>

#### Data collection

Patients were included into the registry at the time of SAVR or TAVI; for patients undergoing MT the date of hospitalisation for multimodal evaluation was determined as the date of inclusion. Follow-up was performed by means of standardised telephone interviews or clinical visits. Between March and October 2013 we performed a sweep follow-up for all patients. Medical records, discharge summaries and documentation of hospitalisation were systematically collected from referring hospitals and general practitioners. Patients and procedure characteristics as well as follow-up data were entered into a dedicated database held at the Clinical Trials Unit in Bern, Switzerland.

#### Definitions

The definitions applied for the analysis have been reported in detail previously<sup>3</sup> and are summarised in the online supplementary material. All events were adjudicated by a team of interventional cardiologists and cardiac surgeons.

#### Statistical analysis

Continuous variables are presented as mean±SD if their distribution is approximately normal and as median/range otherwise. The means were compared using analysis of variance and the

### Valvular heart disease

differences in medians were evaluated with Mann-Whitney or Kruskal-Wallis tests. Categorical data are expressed as frequency (percentages), and were compared using  $\chi^2$  and Fisher's exact tests. Survival was estimated using the Kaplan-Meier method and differences in estimates were compared by means of the log-rank test. All time-to-event analyses were based on the initial treatment allocation, in analogy to the intention-to-treat principle unless otherwise specified. The at-risk time span was derived from the date of intervention on one side and the last available date of a patient on the other side, determined either by the date of death, of the last follow-up or information coming from referring hospitals and practitioners. Univariate and multivariate Cox proportional hazards models were used to derive crude and adjusted survival estimates and to assess the association of baseline characteristics with clinical outcomes. All p values and 95% CIs are two-sided and all analyses were performed using STATA release V.13.

#### RESULTS

Between April 2007 and September 2010, 452 patients with severe aortic stenosis at increased risk for surgery were assessed by the Heart Team. Ten patients died before definitive treatment allocation, 78 patients were assigned to MT, SAVR was performed in 107 patients and 257 patients underwent TAVI (see online supplementary figure S1). Patient characteristics at the time of the intervention are summarised in table 1 and online supplementary table S1. Whereas patients in the MT and the TAVI arms were comparable in terms of baseline characteristics

#### Table 1 Baseline characteristics

	Overall	MT	SAVR	TAVI	
	n=442	n=78	n=107	n=257	p Value
Age: median (IQR)	83 (8)	84 (7)	80 (8)	83 (7)	<0.001
Women	230 (52.0%)	33 (42.3%)	53 (49.5%)	144 (56.0%)	0.090
BMI (kg/m <sup>2</sup> ): mean (SD)	25.6 (4.8)	24.4 (3.5)	26.0 (4.7)	25.8 (5.1)	0.030
Cardiac risk factors					
Hypertension	338 (76.5%)	52 (66.7%)	85 (79.4%)	201 (78.2%)	0.080
Current smoker	65 (14.7%)	7 (9.0%)	16 (15.0%)	42 (16.3%)	0.270
Diabetes mellitus	101 (22.9%)	18 (23.1%)	21 (19.6%)	62 (24.1%)	0.650
Hypercholesterolaemia	233 (52.7%)	32 (41.0%)	46 (43.0%)	155 (60.3%)	0.001
Past medical history					
Prior MI	79 (17.9%)	23 (29.5%)	9 (8.4%)	47 (18.3%)	0.001
Prior PCI	77 (17.4%)	10 (12.8%)	9 (8.4%)	58 (22.6%)	0.003
CABG	76 (17.2%)	18 (23.1%)	4 (3.7%)	54 (21.0%)	<0.001
Stroke	44 (10.0%)	13 (16.7%)	8 (7.5%)	23 (9.0%)	0.080
PVD	93 (21.0%)	16 (20.5%)	13 (12.1%)	64 (24.9%)	0.030
Symptoms					
NYHA III or IV	251 (56.9%)	48 (62.3%)	48 (44.9%)	155 (60.3%)	0.014
Angina	157 (35.5%)	27 (34.6%)	55 (51.4%)	75 (29.2%)	<0.001
Syncope	51 (11.5%)	14 (18%)	13 (12.1%)	24 (9.3%)	0.110
Atrial fibrillation	105 (23.8%)	20 (25.6%)	19 (17.8%)	66 (25.7%)	0.250
Risk assessment					
Log. EuroSCORE: median (IQR)	19.1 (19.9)	25.8 (22.5)	9.8 (8.2)	22.4 (19.9)	<0.001
Lin. EuroSCORE: median (IQR)	10 (4)	11 (2)	8 (2)	11 (3)	<0.001
STS score: median (IQR)	4.7 (3.6)	5.4 (4.7)	3.4 (2.7)	5.1 (3.8)	<0.001
Medications					
Acetylsalicylic acid	254 (57.5%)	39 (50.0%)	59 (55.1%)	156 (60.7%)	0.210
Clopidogrel	62 (14.0%)	10 (12.8%)	5 (4.7%)	47 (18.3%)	0.003
Oral anticoagulation	114 (25.8%)	22 (28.2%)	18 (16.8%)	74 (28.8%)	0.050

BMI, body mass index; CABG, coronary artery bypass grafting; MI, myocardial infarction; MT, medical treatment; NYHA, New York Heart Association; PCI, percutaneous coronary intervention; PVD, peripheral vascular disease; SAVR, surgical aortic valve replacement, TAVI, transcatheter aortic valve implantation.

#### Table 2 Long-term clinical outcome

	Overall	MT	SAVR	TAVI	
	n=442	n=78	n=107	n=257	p diff. between group
At 3 years					
All-cause death	182 (41.2%)	55 (70.5%)	33 (30.8%)	94 (36.6%)	<0.001
Cardiovascular death	132 (29.9%)	52 (66.7%)	18 (16.8%)	62 (24.1%)	<0.001
MI	7 (1.6%)	2 (2.6%)	0 (0.0%)	5 (2.0%)	0.266
Major stroke	23 (5.2%)	3 (3.9%)	8 (7.5%)	12 (4.7%)	0.463
Minor stroke/TIA	5 (1.1%)	0 (0.0%)	3 (2.8%)	2 (0.8%)	0.167
All-cause death or major stroke	189 (42.8%)	56 (71.8%)	36 (33.6%)	97 (37.7%)	<0.001
All-cause death, major stroke or MI	192 (43.3%)	57 (73.1%)	36 (33.6%)	99 (38.5%)	<0.001
At 5 years					
All-cause death	213 (48.2%)	63 (80.8%)	39 (36.5%)	111 (43.2%)	<0.001
Cardiovascular death	157 (35.5%)	60 (76.9%)	24 (22.4%)	73 (28.4%)	<0.001
MI	10 (2.3%)	2 (2.6%)	0 (0.0%)	8 (3.1%)	0.169
Major stroke	25 (5.7%)	3 (3.9%)	9 (8.4%)	13 (5.1%)	0.379
Minor stroke/TIA	6 (1.4%)	0 (0.0%)	3 (2.8%)	3 (1.2%)	0.316
All-cause death or major stroke	221 (50.0%)	64 (82.1%)	42 (39.3%)	115 (44.8%)	<0.001
All-cause death, major stroke or MI	227 (51.4%)	65 (83.3%)	42 (39.3%)	120 (46.7%)	<0.001

Values given are n (%) and the differences between groups were evaluated using Pearson's  $\chi^2$  and Fisher's exact tests.

MI, myocardial infarction; MT, medical treatment; SAVR, surgical aortic valve replacement; TAVI, transcatheter aortic valve implantation; TIA, transient ischaemic attack.

and estimated periprocedural risk, patients allocated to SAVR tended to be younger, had less comorbidities and lower calculated risk.

#### **Clinical outcome**

Periprocedural outcome has been reported previously. All comparisons between the three treatment arms are descriptive. The median duration of follow-up of patients undergoing MT, SAVR or TAVI amounted to 4.6 (range 3.4–6.5) years, 3.8 (range 2.8– 6.1) years and 3.9 (range 2.6–5.8) years, respectively. One patient was lost to follow-up 2.8 years after SAVR. Event rates at 3 years and 5 years are summarised in table 2. There was a statistically significant association between the mortality rate and the type of treatment after 3 years and 5 years. Rates of myocardial infarction and cerebrovascular events were low without significant differences between groups. All-cause mortality through 5 years amounted to 81%, 37% and 43%, among patients allocated to MT, SAVR and TAVI, respectively (p<0.001; figure 1).



**Figure 1** Cumulative incidence of all-cause mortality according to treatment strategy up to 5 years of follow-up. Medical treatment (black line), surgical aortic valve replacement (SAVR) (red line), transcatheter aortic valve implantation (TAVI) (blue line).

Crude and adjusted HRs for comparisons between groups are provided in online supplementary table S2. At 5 years of follow-up, the risk of the composite of all-cause death, major stroke and myocardial infarction was significantly lower for patients in the SAVR and TAVI groups as compared with the MT group in crude and adjusted analyses (SAVR vs MT: adj HR 0.31, 95% CI 0.21 to 0.46; TAVI vs MT: adj HR 0.34, 95% CI 0.25 to 0.46; figure 2). The difference was driven by all-cause mortality. No statistically significant difference in the risk of all-cause death, stroke and major myocardial infarction was observed between patients treated with SAVR or TAVI (SAVR vs TAVI: adj HR 0.88, 95% CI 0.62 to 1.25). A stratified comparison among major subgroups (age  $\geq$ 80 years, gender, STS-score  $\geq$ 5 and LVEF <40%) between patients undergoing intervention (SAVR or TAVI) versus MT demonstrated a consistent benefit for patients allocated to



**Figure 2** Cumulative incidence of major adverse cerebro-cardiovascular events defined as the combined end point of all-cause mortality, major stroke or myocardial infarction (MI) according to treatment strategy up to 5 years of follow-up. Medical treatment (black line), surgical aortic valve replacement (SAVR) (red line), transcatheter aortic valve implantation (TAVI) (blue line).

**Figure 3** Stratified analysis for all-cause mortality in major subgroups undergoing intervention (surgical aortic valve replacement (SAVR) or transcatheter aortic valve implantation (TAVI)) versus patients undergoing medical treatment. Black squares represent HRs; horizontal black lines illustrate CIs. A HR >1 (right side) is in favour of medical treatment, whereas a HR <1 (left side) is in favour of intervention (SAVR or TAVI). STS, Society of Thoracic Surgeons.

	Stratified analysis for mortality at 5 years						
	SAVR/TAVI n (%)	Medical n (%)	HR (95% CI)		p-value	p-value interaction	
Overall	150 (41.2)	63 (80.8)	0.32 (0.24-0.44)	<b>⊢</b> •−1	<0.001		
Age						0.268	
<80 years	38 (33.6)	14 (82.3)	0.23 (0.13-0.44)	<b>⊢</b>	<0.001		
≥80 years	112 (44.6)	49 (80.3)	0.37 (0.26-0.52)	<b></b>	<0.001		
Gender						0.083	
Male	73 (43.7)	42 (93.3)	0.25 (0.17-0.37)	<b>⊢</b> ∎–-1	<0.001		
Female	77 (39.1)	21 (63.6)	0.45 (0.28-0.74)	<b>⊢</b> •−−+	0.001		
STS score						0.2	
<5	67 (32.8)	21 (65.6)	0.41 (0.25-0.67)	<b>—</b> •— I	<0.001		
≥5	83 (51.9)	41 (91.1)	0.29 (0.20-0.43)	<b></b>	<0.001		
LVEF						0.227	
≥40%	113 (40.9)	32 (78.1)	0.39 (0.26-0.58)	<b></b>	<0.001		
<40%	29 (48.3)	27 (90)	0.28 (0.16-0.48)	<b>⊢</b> −−→	<0.001		
				· · · · · · · · · · · · · · · · · · ·			
				0.1 0.25 0.5 1	2 4		

one of the two intervention arms (figure 3). After exclusion of the MT arm, a stratified analysis across subgroups between patients undergoing SAVR or TAVI identified no statistically significant differences between the two treatment strategies (see online supplementary figure S2).

#### Cross-over from MT to SAVR or TAVI

During the follow-up period, 11 of the 78 patients (14%) initially assigned to MT were reassessed and crossed over to TAVI (n=9) or SAVR (n=2) after a median of 2.0 years (range 25-1159 days). Seven patients initially allocated to the MT group changed their mind and agreed to undergo TAVI (n=6) or SAVR (n=1). Four patients deemed poor candidates for intervention by the initial Heart Team consensus underwent cross-over to TAVI (n=3) or SAVR (n=1) after reassessment. There were no statistically significant differences in the baseline characteristics reported in table 1 between patients with or without cross-over from MT to one of the intervention arms, except for the STS score, which was significantly higher among the patients who did not cross over (p=0.029). The majority of long-term survivors in the MT arm had undergone cross-over during the course of the study. After 5 years, only 6% of the patients who did not undergo conversion were alive, whereas the survival rate was 100% for the ones who subsequently underwent SAVR and 67% for those who underwent TAVI. The association between death and conversion either to SAVR or TAVI was statistically significant (p<0.001). A survival analysis of the overall population as-treated is depicted in figure 4.

#### **Predictors of mortality**

In multivariate analyses, SAVR (HR 0.39, 95% CI 0.24 to 0.61, p<0.001), TAVI (HR 0.37, 95% CI 0.26 to 0.52, p<0.001) and female gender (HR 0.72, 95% CI 0.53 to 0.99, p=0.042) were associated with improved survival. Conversely, body mass index (BMI)  $\leq 20 \text{ kg/m}^2$  (HR 1.60, 95% CI 1.04 to 2.47, p=0.032), diabetes (HR 1.48, 95% CI 1.03 to 2.12, p=0.033), peripheral vascular disease (HR 2.01, 95% CI 1.28 to 2.37, p<0.001) and severe pulmonary hypertension (HR 1.43, 95% CI 1.03 to 2.00, p=0.034) were identified as independent predictors of all-cause mortality through 5 years of follow-up (table 3). After exclusion of patients in the MT arm, a BMI  $\leq 20 \text{ kg/m}^2$ , a history of stroke, a history of peripheral vascular disease and

atrial fibrillation were identified as predictors of long-term mortality (see online supplementary table S3).

# Echocardiographic follow-up and valve-related reinterventions

Echocardiographic follow-up was performed after a median of 3.3 years (range 3–1936 days) and 1.6 years (range 246–1651 days) in patients undergoing SAVR or TAVI, respectively, (p<0.001). Due to the differing time intervals, the results must be considered descriptive. The mean trans-prosthetic gradient among patients of the TAVI group was significantly lower compared with patients of the SAVR group (see online supplementary figure S3). No statistically significant difference between the two treatment arms was documented with respect to the aortic valve area (TAVI  $1.7\pm0.7$  cm<sup>2</sup> vs SAVR  $1.4\pm0.4$  cm<sup>2</sup>, p=0.11). Conversely, moderate or severe aortic regurgitation was more common among patients treated with TAVI as compared with SAVR (14.3% vs 3.1%, p<0.001).

Valve-related repeat interventions beyond the periprocedural period were performed in five patients (1.9%) in the TAVI cohort. In contrast, none of the patients of the SAVR group required a valve-related repeat intervention (p=0.327). Two





#### Table 3 Predictors of all-cause mortality at 5 years

	Alive	Dead	Univariate HR (95% CI)	p Value	Multivariate HR (95% CI)	p Value
Type of intervention				<0.001		<0.001
Medical	15 (6.5%)	63 (29.6%)	Reference		Reference	
SAVR	68 (29.7%)	39 (18.3%)	0.29 (0.19–0.43)		0.39 (0.24–0.61)	
TAVI	146 (63.8%)	111 (52.1%)	0.34 (0.25–0.46)		0.37 (0.26-0.52)	
Age ≥80 years	151 (65.9%)	161 (75.6%)	1.38 (1.01–1.89)	0.045	1.39 (0.98–1.97)	0.067
Female	132 (57.6%)	98 (46.0%)	0.70 (0.53–0.92)	0.010	0.72 (0.53–0.99)	0.042
BMI $\leq$ 20 kg/m <sup>2</sup>	18 (7.9%)	28 (13.2%)	1.42 (0.94–2.15)	0.091	1.60 (1.04–2.47)	0.032
Hypertension	176 (76.9%)	162 (76.1%)	0.97 (0.71–1.33)	0.851	_	
Diabetes	45 (19.7%)	56 (26.3%)	1.26 (0.93–1.72)	0.136	1.48 (1.03–2.12)	0.033
Hypercholesterolaemia	123 (53.7%)	110 (51.6%)	0.90 (0.69–1.18)	0.463	_	
History of CHD	132 (57.6%)	138 (64.8%)	1.23 (0.93–1.65)	0.139	1.13 (0.82–1.58)	0.453
History of MI	34 (14.9%)	45 (21.1%)	1.33 (0.95–1.85)	0.095	0.81 (0.55–1.21)	0.306
History of CABG	34 (14.9%)	42 (19.7%)	1.27 (0.90–1.78)	0.170	0.87 (0.57–1.34)	0.529
History of stroke	14 (6.1%)	30 (14.1%)	1.94 (1.32–2.85)	0.001	1.52 (1.00–2.32)	0.051
History of PVD	31 (13.5%)	62 (29.1%)	1.90 (1.41–2.56)	<0.001	2.01 (1.44–2.81)	< 0.001
History of atrial fibrillation	35 (15.3%)	70 (32.9%)	1.95 (1.46–2.60)	<0.001	1.74 (1.28–2.37)	< 0.001
LVEF <40%	34 (16.5%)	56 (27.9%)	1.71 (1.26–2.33)	0.001	1.25 (0.89–1.76)	0.202
Peak PA pressure ≥60 mm Hg	40 (17.5%)	55 (25.8%)	1.50 (1.10–2.04)	0.010	1.43 (1.03–2.00)	0.034

Values given are n (%) or HR (95% CI). Only variables with a p value <0.25 in the univariate analysis were included in the multivariate model.

BMI, body mass index; CABG, coronary artery bypass grafting; CHD, coronary heart disease; MI, myocardial infarction; PA, pulmonary artery; PVD, peripheral vascular disease; SAVR, surgical aortic valve replacement; TAVI, transcatheter aortic valve implantation.

patients underwent balloon dilatation of the transcatheter prosthesis due to paravalvular regurgitation 13 days and 14 days after TAVI. One patient was diagnosed with an aorto-right ventricular fistula 38 days after implantation of an Edwards SAPIEN prosthesis which was occluded with a coil.<sup>4</sup> One patient developed severe paravalvular aortic regurgitation 1.3 years after implantation of a Medtronic CoreValve bioprosthesis and was treated with valve-in-valve implantation of a second Medtronic CoreValve bioprosthesis. And one patient developed severe valvular deterioration 4.6 years after implantation of an Edwards SAPIEN prosthesis (mean gradient 64 mm Hg, aortic valve area (AVA) 0.6 cm<sup>2</sup>) and was treated successfully by valve-in-valve- implantation (Medtronic CoreValve bioprosthesis).

#### DISCUSSION

We present clinical outcomes of elderly patients with severe symptomatic aortic stenosis at increased risk for surgery as a function of treatment modality through 5 years of follow-up. The key findings of our analysis can be summarised as follows: (1) TAVI and SAVR improve long-term survival compared with MT; (2) there were no statistically significant differences in rates of major adverse cerebro-cardiovascular events between patients allocated to SAVR and TAVI through 5 years of follow-up; (3) male gender, low BMI, diabetes, peripheral vascular disease, atrial fibrillation and severe pulmonary hypertension were identified as independent predictors of mortality at 5 years; (4) repeat interventions for prosthetic heart valve related problems were rare and were observed in TAVI patients only; (5) patients with cross-over from medical therapy to SAVR or transcatheter aorticvalve replacement (TAVR) had a reasonably good outcome whereas those who did not had a dismal prognosis.

As reported previously, a considerable proportion of patients in the MT arm refused intervention despite a recommendation by the Heart Team.<sup>3</sup> TAVI and SAVR decreased the absolute risk of mortality through 5 years of follow-up by approximately 70% with low rates of myocardial infarction or cerebrovascular events. Our findings are in line with the 2-year results of the randomised PARTNER B trial showing an absolute risk reduction of 42% and 43% in the first 2 years after randomisation among patients treated with TAVI compared with MT, respectively.<sup>2</sup> In our analysis, the time-to-event curves between patients who underwent SAVR or TAVI and those who underwent MT diverged until 2 years after treatment allocation and run approximately in parallel for the follow-up beyond 2 years. This finding persisted in an 'as-treated' analysis and was not attributable to the patients in the MT arm with cross-over to intervention.

Efficacy of TAVI or SAVR was also apparent among patients who subsequently crossed over to an intervention. Patients with cross-over from MT to TAVI or SAVR were comparable in terms of baseline characteristics to patients who continued with MT. However, mortality was significantly lower among patients who crossed over compared with those who continued MT. This finding highlights the fact that the process of decision-making can be challenging within the Heart Team and patients with only moderate symptoms may refuse active treatment owing to fear of complications or acceptable quality of life under MT alone.

Rates of adverse events showed no significant differences between patients allocated to SAVR or TAVI with respect to major adverse cerebro-cardiovascular events throughout 5 years of follow-up despite differences in baseline characteristics. This is in line with the randomised comparison of SAVR and TAVI in the PARTNER A trial without differences in all-cause mortality or stroke throughout 3 years of follow-up.<sup>5</sup> Rates of myocardial infarction and stroke were low in all groups during this follow-up period.

When assessing predictors of all-cause mortality at 5 years in a multivariate analysis, male gender, low BMI, diabetes, peripheral vascular disease, atrial fibrillation and severe pulmonary hypertension emerged as independent predictors. Low BMI is one of the determinants of frailty that has previously been associated with adverse outcome after TAVI6 7 and remains an important piece in the puzzle for further improvements in this patient population. An appropriate assessment of frailty followed by a dedicated intervention before TAVI or SAVR might therefore be an additional strategy to guide patient selection. Diabetes also emerged an independent predictor of mortality confirming the findings of previous studies.<sup>8</sup> A subanalysis of the PARTNER trial reported the effect of diabetes on outcomes and hypothesised improved survival of patients undergoing TAVI compared with SAVR (18.0% vs 27.4%, HR 0.60, 95% CI 0.36 to 0.99, p=0.04).<sup>9</sup> Peripheral vascular disease, but not coronary artery disease was identified as an independent predictor in the present analysis. We have documented in a larger cohort of patients undergoing TAVI an association of advanced coronary artery disease with an increased risk of cardiac mortality.<sup>10</sup> This finding may be related to the fact that peripheral vascular disease is a marker of atherosclerotic disease burden in general. Furthermore, patients with peripheral vascular disease have an increased risk of cerebrovascular events but also elevated rates of vascular access site complications. Another unfavourable marker is atrial fibrillation which has been associated with adverse outcome in previous studies.<sup>11</sup> Finally, severe pulmonary hypertension has previously been associated with an increased risk of mortality after TAVI.<sup>12</sup> In patients with fixed pulmonary hypertension, the poor outcome may be related to right heart failure despite successful elimination of the increased afterload imposed by the stenotic valve.

Another important consideration is valve durability after TAVI and SAVR. The low incidence of repeat interventions due to prosthetic heart valve complications among TAVI patients is reassuring. Only two patients (1.9%) in the present cohort experienced late valve degeneration which was successfully treated by valve-in-valve intervention. The limited echocardiographic evaluation, although not prospectively defined, showed sustained low transvalvular gradients. This finding is supported by a recent publication by Toggweiler *et al*<sup>13</sup> reporting on favourable haemodynamic outcome of patients treated with TAVI through 5 years of follow-up. Mild valvular aortic regurgitation was documented in 7.1% of 88 patients, and 3 patients (3.4%) were found to have moderate valvular aortic regurgitation or stenosis at 5 years of follow-up.<sup>13</sup> Rates of mild or moderate valvular aortic regurgitation as assessed by echocardiography were higher among patients undergoing TAVI as compared with SAVR (p < 0.001).

Our analysis has several limitations. First, the patients were referred from affiliated medical centres and allocated to the different treatment strategies in a non-randomised fashion. We present adjusted analyses to correct for the selection bias. However, latent factors may have been underappreciated in our analysis. Second, we report on a relatively small cohort of patients. In turn, follow-up was almost complete and reports on long-term outcome of patients undergoing TAVI are scarce. Third, not all patients underwent echocardiographic follow-up and the duration of follow-up was considerably longer among patients who underwent SAVR as compared with those who underwent TAVI. Furthermore, patients with pathological findings on previous examinations might have been summoned up more regularly than patients with normal valvular function.

In summary, the current analysis confirms comparable clinical outcomes of TAVI and SAVR during long-term follow-up in a selected patient population. No statistically significant difference in outcome apart from the higher rate of residual aortic regurgitation in disfavour of the TAVI population was found. In contrast, MT was associated with a dismal prognosis unless patients underwent conversion of treatment to SAVR or TAVI at a later stage.

#### Key messages

#### What is known on this subject?

Evidence from randomised clinical trials showed a sustained survival benefit of transcatheter aortic valve implantation (TAVI) compared with medical treatment (MT) in inoperable patients as well as similar survival as surgical aortic valve replacement (SAVR) among patients at high risk for surgery through 2 years of follow-up.

#### What might this study add?

This study provides long-term outcome through 5 years of a consecutive unselected cohort of patients at increased risk allocated to either one of all currently available strategies for the treatment of severe aortic stenosis. The study shows similar rates of major adverse cerebro-cardiovascular events for TAVI and SAVR, and dismal prognosis for patients undergoing MT. The study identifies low body mass index, diabetes, peripheral vascular disease, atrial fibrillation and pulmonary hypertension as independent predictors of mortality.

#### How might this impact on clinical practice?

The study might improve the selection of adequate candidates for TAVI and SAVR.

**Contributors** TP: Study design, data collection, data analysis and writing. LE: Study design, data collection and writing. MR and CH: Data analysis and writing. SS: Data collection and analysis. OC, FP, LB and BL: Data collection. CJO: Study design and data collection. BM: Writing. PJ: Data analysis. TC and SW: Study design, data collection and writing. PW: Study design, data collection, data analysis and writing.

**Funding** PW: Proctoring and lecture fees from Edwards Lifesciences and Medtronic; Research grant to the institution (University of Berne) from Medtronic. CH: Proctoring and lecture fees from Edwards Life Sciences and Symetis; consultancy for Medtronic. SW: Research grants to the institution from Biotronik and St Jude.

Patient consent Obtained.

Ethics approval Bern Ethics Committee.

Provenance and peer review Not commissioned; externally peer reviewed.

#### REFERENCES

- Kodali SK, Williams MR, Smith CR, et al. Two-year outcomes after transcatheter or surgical aortic-valve replacement. N Engl J Med 2012;366:1686–95.
- 2 Makkar RR, Fontana GP, Jilaihawi H, et al. Transcatheter aortic-valve replacement for inoperable severe aortic stenosis. N Engl J Med 2012; 366:1696–704.
- 3 Wenaweser P, Pilgrim T, Kadner A, et al. Clinical Outcomes of patients with severe aortic stenosis at increased surgical risk according to treatment modality. J Am Coll Cardiol 2011;58:2151–62.
- 4 Pilgrim T, Meier B, Wenaweser P. Aorto-right ventricular fistula after transfemoral aortic valve implantation. *J Invasive Cardiol* 2010;22:E30–1.
- 5 Thourani VH. Three-year outcomes after transcatheter or surgical aortic valve replacement in high-risk patients with severe aortic stenosis. *Presented at: American College of Cardiology Scientific Session/i2 Summit*; March 11, 2013; San Francisco, CA, USA.
- 6 Wenaweser P, Pilgrim T, Kadner A, et al. Clinical outcome and predictors for adverse events after transcatheter aortic valve implantation with the use of different devices and access routes. Am Heart J 2011;108:195–201.
- 7 Schoenenberger AW, Stortecky S, Neumann S, et al. Predictors of functional decline in elderly patients undergoing transcatheter aortic valve implantation (TAVI). Eur Heart J 2013;34:684–92.

## Valvular heart disease

- 8 Conrotto F, D'Ascenzo F, Giordana F, et al. Impact of diabetes mellitus on early and midterm outcomes after transcatheter aortic valve implantation (from a multicenter registry). Am J Cardiol 2014;113:529–34.
- 9 Lindman BR, Pibarot P, Arnold SV, et al. Transcatheter versus surgical aortic valve replacement in patients with diabetes and severe aortic stenosis at high risk for surgery: an analysis of the PARTNER trial. J Am Coll Cardiol 2014;63:1090–9.
- 10 Stefanini GG, Stortecky S, Cao D, et al. Coronary artery disease severity and aortic stenosis: clinical outcomes according to SYNTAX-score in patients undergoing transcatheter aortic valve implantation. Eur Heart J 2014. In press.
- 11 Stortecky S, Buellesfeld L, Wenaweser P, et al. Atrial fibrillation and aortic stenosis: impact on clinical outcomes among patients undergoing transcatheter aortic valve implantation. *Circ Cardiovasc Interv* 2013; 6:77–84.
- 12 Ben-Dor I, Goldstein SA, Pichard AD, et al. Clinical profile, prognostic implication, and response to treatment of pulmonary hypertension in patients with severe aortic stenosis. Am J Cardiol 2011;107:1046–51.
- 13 Toggweiler S, Humphries KH, Lee M, *et al.* 5-year outcome after transcatheter aortic valve implantation. *J Am Coll Cardiol* 2013;61:413–19.

## **Online Supplement**

# Longterm Outcome of Elderly Patients with Severe Aortic Stenosis as a Function of Treatment Modality

Thomas Pilgrim, MD<sup>‡</sup>; Lars Englberger, MD<sup>¶</sup>; Martina Rothenbühler, MSc<sup>†</sup>; Stefan Stortecky, MD<sup>‡</sup>;

Osman Ceylan, MS<sup>‡</sup>; Crochan J. O'Sullivan, MD<sup>‡</sup>; Christoph Huber, MD<sup>¶</sup>; Fabien Praz, MD<sup>‡</sup>; Lutz

Buellesfeld, MD<sup>‡</sup>; Bettina Langhammer, MD<sup>¶</sup>; Bernhard Meier, MD<sup>‡</sup>; Peter Jüni, MD<sup>†</sup>; Thierry Carrel,

MD<sup>1</sup>; Stephan Windecker, MD<sup>‡</sup>; Peter Wenaweser, MD<sup>‡</sup>

<sup>‡</sup>Departments of Cardiology and ¶Cardiovascular Surgery, Swiss Cardiovascular Center Bern, <sup>†</sup>Institute of Social and Preventive Medicine and Clinical Trials Unit, Bern University Hospital, Bern, Switzerland

Corresponding Author:

Peter Wenaweser, MD Department of Cardiology Swiss Cardiovascular Center Bern Bern University Hospital CH-3010 Bern Switzerland Email: <u>peter.wenaweser@insel.ch</u> Phone: +41 31 632 21 11 Fax: +41 31 632 47 70

## **Inclusion criteria**

(1) severe aortic stenosis with an echocardiographic transaortic valvular mean gradient >40 mmHg or a calculated aortic valve area <1 cm<sup>2</sup>; (2) age ≥80 years in the presence of a logistic EuroSCORE >15%. Younger patients were eligible in case of a previous history of cardiac surgery, chronic obstructive pulmonary disease (forced expiratory volume during one second <1.0), severe pulmonary hypertension (≥60 mmHg), porcelain aorta, history of radiation therapy to the mediastinum, or frailty (BMI <18 kg/m<sup>2</sup>).

### Multimodal assessment of patients with severe aortic stenosis

The evaluation included left and right heart catheterization, aortography, transthoracic (TTE) and transesophageal echocardiography (TEE), and CT angiography of the chest, abdomen, and pelvis. Subspecialty assessment was requested for comorbidities such as malignancies, chronic pulmonary disease, renal failure, liver cirrhosis, and bleeding diathesis. Risk estimation was complemented by the use of the linear and logistic EuroSCORE and the STS score (1). Reasons for treatment allocation were based upon anatomical and technical considerations, estimated peri-procedural risk, and patient preference, and have been reported previously (2).

The decision to perform coronary revascularization was based on angiographic findings. Complete revascularization by means of arterial or venous conduits was aimed at in the majority of patients undergoing SAVR. Among patients with TAVI, revascularization by PCI was performed in proximal coronary segments with a diameter stenosis ≥70% either in a scheduled session prior to TAVI or concomitant with TAVI.

## Definitions

Cardiac death was considered in case of death secondary to a proximate cardiac cause and assumed in case of an unknown cause of death. We differentiated between spontaneous and peri-procedural myocardial infarction. Spontaneous myocardial infarction was defined as an elevation of at least one value of a cardiac biomarker above the 99<sup>th</sup> percentile of the upper reference limit >72 hours after intervention in combination with evidence of myocardial ischemia determined by one of the following: ECG changes indicative of new ischemia, new pathological Q waves in at least 2 contiguous leads, or imaging evidence of new loss of viable myocardium or new wall motion abnormality. Periprocedural myocardial infarction was considered in the setting of new ischemic signs or symptoms in the presence of elevated cardiac biomarkers (two or more post-procedure samples that were >6-8 hours apart with a 20% increase in the second sample and a peak value exceeding 10x the 99<sup>th</sup> percentile upper reference limit (URL), or a peak value exceeding 5x the 99<sup>th</sup> percentile URL with new pathological Q waves in at least two contiguous leads) within 72 hours after the index procedure. Major stroke was documented in case of a rapid onset of focal or global neurological deficit of  $\geq$ 24 hours duration, requiring therapeutic intervention, or documentation of a new intracranial defect using MRI or CT-scan. Transient ischemic attack (TIA) was determined as a neurologic deficit with complete remission within 24 hours of onset. The combination of all-cause mortality, spontaneous and peri-procedural myocardial infarction, and major stroke was recorded as Major Adverse Cerebro-Cardiovascular Events (MACCE).

3

## References

- 1 Nashef SA, Roques F, Michel P, Gauducheau E, Lemeshow S, Salamon R. European system for cardiac operative risk evaluation (EuroSCORE). Eur J Cardiothorac Surg. 1999;16(1):9-13.
- 2 Wenaweser P, Pilgrim T, Kadner A, et al. Clinical Outcomes of patients with severe aortic stenosis at increased surgical risk according to treatment modality. J Am Coll Cardiol 2011;58(21):2151-62.

## **Figure Legends**

**Suppl. Figure 1** Patient flow according to CONSORT statement.

- Suppl Figure 2Stratified analysis for all-cause mortality in major subgroups undergoing<br/>surgical aortic valve replacement [SAVR] or transcatheter aortic valve<br/>implantation [TAVI]. Black squares represent hazard ratios (HR); horizontal<br/>black lines illustrate confidence intervals (CI). An HR >1 (right side) is in favour<br/>of SAVR, whereas an HR <1 (left side) is in favor of TAVI.</th>
- Suppl. Figure 3Transvalvular mean gradients over time. Surgical aortic valve replacement<br/>(SAVR) (red line), transcatheter aortic valve implantation (TAVI) (blue line).

Suppl. Table 1	Imaging characteristics					
	Overall	MT	SAVR	ΤΑνι	p-value	
Variable	n = 442	n = 78	n = 107	n = 257		
Echocardiography						
LVEF %: median (IQR)	60 (25)	50 (30)	60 (15)	55 (25)	<0.001	
Mean gradient (mm Hg): median (IQR)	45 (23)	37 (27)	54 (18)	45 (21)	<0.001	
AVA (cm <sup>2</sup> ): median (IQR)	0.6 (0.3)	0.6 (0.3)	0.6 (0.3)	0.6 (0.3)	0.490	
Cardiac catheterization						
Coronary artery disease	270 (61.1%)	47 (60.3%)	56 (52.3%)	167 (65.0%)	0.080	
Mean gradient (mmHg): median (IQR)	43 (21.3)	36 (22)	48 (26)	42 (20)	<0.001	
AVA (cm <sup>2</sup> ): median (IQR)	0.5 (0.3)	0.6 (0.4)	0.5 (0.2)	0.5 (0.3)	0.090	
Peak PA pressure ≥60 mm Hg	95 (21.5%)	19 (24.4%)	15 (14.0%)	61 (23.7%)	0.100	

AVA: aortic valve area; IQR: interquartile range; LVEF: left ventricular ejection fraction; PA: pulmonary artery

Suppl. Table 2	Longterm clinical outcome, crude and adjusted hazard ratios								
	SAVR vs.	Medical	TAVI vs.	Medical	SAVR v	vs. TAVI			
	Crude	Adjusted	Crude	Adjusted	Crude	Adjusted			
At 3 years									
All-cause death	0.30 (0.19-0.46)	0.30 (0.19-0.47)	0.33 (0.23-0.46)	0.31 (0.22-0.44)	0.85 (0.57-1.27)	0.89 (0.60-1.32)			
Cardiovascular death	0.17 (0.10-0.30)	0.17 (0.10-0.30)	0.23 (0.16-0.33)	0.21 (0.14-0.31)	0.72 (0.42-1.22)	0.75 (0.44-1.27)			
Major stroke	1.34 (0.35-5.15)	1.03 (0.26-4.13)	0.94 (0.26-3.44)	0.91 (0.25-3.32)	1.86 (0.74-4.72)	1.94 (0.76-4.92)			
All-cause death or major stroke	0.30 (0.19-0.46)	0.30 (0.19-0.47)	0.33 (0.24-0.46)	0.31 (0.22-0.44)	0.84 (0.57-1.26)	0.88 (0.59-1.31)			
All-cause death, major stroke, or MI	0.32 (0.21-0.48)	0.32 (0.21-0.49)	0.34 (0.24-0.47)	0.32 (0.23-0.45)	0.90 (0.61-1.32)	0.93 (0.63-1.36)			
At 5 years									
All-cause death	0.30 (0.20-0.45)	0.30 (0.20-0.45)	0.34 (0.25-0.46)	0.32 (0.23-0.44)	0.84 (0.58-1.21)	0.87 (0.61-1.26)			
Cardiovascular death	0.19 (0.12-0.31)	0.18 (0.11-0.30)	0.23 (0.16-0.33)	0.22 (0.15-0.31)	0.80 (0.50-1.27)	0.83 (0.52-1.32)			
Major stroke	1.52 (0.40-5.71)	1.19 (0.31-4.61)	1.01 (0.28-3.65)	0.99 (0.27-3.55)	1.91 (0.79-4.60)	1.96 (0.81-4.75)			
All-cause death or major stroke	0.32 (0.21-0.47)	0.32 (0.21-0.47)	0.34 (0.25-0.47)	0.33 (0.24-0.45)	0.87 (0.61-1.24)	0.90 (0.63-1.29)			
All-cause death, major stroke, or MI	0.31 (0.21-0.46)	0.31 (0.21-0.46)	0.35 (0.26-0.48)	0.34 (0.25-0.46)	0.85 (0.60-1.21)	0.88 (0.62-1.25)			

Values are hazard ratio (95% confidence interval). Adjusted for age, sex, BMI, hypertension, current smoking, diabetes, stroke at baseline, peripheral arterial occlusive disease at baseline, atrial fibrillation, left ventricular ejection fraction, PAS pressure. MI: myocardial infarction

Suppl. Table 3	Predictors of	Predictors of all-cause mortality at 5 years for SAVR/TAVI patients					
	Alive	Dead	Univariate HR (95% CI)	p-value	Multivariate HR (95% CI)	p-value	
Type of intervention: TAVI	146 (68.2%)	111 (74.0%)	1.19 (0.83-1.72)	0.349	0.89 (0.60-1.32)	0.574	
Age ≥80 years	139 (65.0%)	112 (74.7%)	1.39 (0.96-2.01)	0.080	1.35 (0.91-2.00)	0.132	
Female	120 (56.1%)	77 (51.3%)	0.84 (0.60-1.16)	0.293			
BMI ≤20kg/m <sup>2</sup>	15 (7.0%)	23 (15.3%)	1.77 (1.10-2.79)	0.017	1.77 (1.09-2.86)	0.021	
Hypertension	169 (79.0%)	117 (78.0%)	0.97 (0.65-1.43)	0.865			
Diabetes	43 (20.1%)	40 (26.7%)	1.25 (0.87-1.81)	0.227	1.43 (0.96-2.12)	0.082	
Hypercholesterolemia	116 (54.2%)	85 (56.7%)	1.05 (0.76-1.45)	0.782			
History of CHD	126 (58.9%)	97 (64.7%)	1.22 (0.87-1.72)	0.243	1.06 (0.73-1.53)	0.776	
History of MI	31 (14.5%)	25 (16.7%)	1.12 (0.72-1.74)	0.608			
History of CABG	31 (14.5%)	27 (18.0%)	1.26 (0.83-1.91)	0.286			
History of stroke	13 (6.1%)	18 (12.0%)	1.88 (1.15-3.09)	0.012	2.04 (1.23-3.40)	0.006	
History of PVD	29 (13.6%)	48 (32.0%)	2.21 (1.57-3.13)	<0.001	2.45 (1.68-3.60)	<0.001	
History of atrial fibrillation	33 (15.4%)	52 (34.7%)	2.22 (1.58-3.11)	<0.001	2.18 (1.52-3.14)	<0.001	
LVEF <40%	31 (16.0%)	29 (20.4%)	1.29 (0.85-1.94)	0.227	1.23 (0.80-1.88)	0.348	
Peak PA pressure ≥60 mm Hg	38 (17.8%)	38 (25.3%)	1.48 (1.03-2.15)	0.036	1.27 (0.86-1.88)	0.231	

## Suppl. Figure 1.

## Figure 1. Patient flow according to the CONSORT statement



	TAVI n (%)	SAVR n (%)	HR (95% CI)		p-value	p-value interactior
Overall	111 (43.2)	39 (36.5)	1.19(0.83-1.72)		0.349	
Age						0.113
<80 years	27 (40.3)	11 (23.9)	1.76(0.87-3.60)		0.113	
≥80 years	84 (44.2)	28 (45.9)	0.92(0.60-1.42)		0.717	
Gender						0.387
Male	54 (47.8)	19 (35.2)	1.41(0.84-2.39)		0.195	
Female	57 (39.6)	20 (37.7)	1.03(0.62-1.72)		0.908	
STS score						0.404
<5	44 (34.9)	23 (29.5)	1.18(0.71-1.96)		0.524	
≥5	67 (51.2)	16 (55.2)	0.84(0.50-1.48)		0.582	
LVEF						0.772
≥40%	82 (42.5)	31 (37.4)	1.12(0.74-1.70)		0.596	
<40%	24 (48)	5 (50)	0.98(0.37-2.57)	⊢I	0.969	
				0.25 0.5 1 2 4		

Suppl Figure 2. Stratifie	ed analysis for mortality at 5 years
---------------------------	--------------------------------------

Suppl. Figure 3.

